Stable Long-term AD Control Seen With Leo’s Tralokinumab
Tralokinumab (Adbry, Leo Pharma) provides stable long-term control of atopic dermatitis (AD), new research shows. The new data, presented at the annual meeting of the American Academy of Dermatology in San Diego, CA, suggests that it’s possible to transition from flare-driven AD treatment with topical therapies to stable disease control with long-term tralokinumab treatment. The new […]